Evaluation Methods for Protein Degrader Activity and Degradation Efficiency

* Our products and services are available to organizations and companies for research use only.

Consult with Our Experts

A protein degrader should be evaluated by the protein it removes, the pathway responsible for that removal, and the conditions under which the effect persists. Binding, reduced cell growth, disappearance from the cell surface, or accumulation in lysosomes can help explain activity, but none independently establishes target degradation. An informative assay package connects direct target measurements with mechanism controls and time-dependent responses. This guide organizes those measurements by degrader type so research teams can select experiments that answer a specific development question rather than collect unrelated assay results.

What Should Be Measured to Confirm Protein Degrader Activity?

Begin with a defined target population: total cellular protein, a particular protein variant, a cell-surface pool, a circulating protein, or an insoluble fraction. Select a primary assay that measures that population and a second method with a different detection principle. For example, a reporter assay can provide screening throughput, while an immunoblot confirms loss of the endogenous full-length protein. Targeted mass spectrometry can provide additional confirmation, although peptide measurements require suitable sample preparation when intact proteins must be distinguished from persistent fragments.

• Amount removed: Calculate target depletion as [1 - (normalized target signal in treated samples / normalized target signal in matched controls)] × 100%. State whether normalization uses cell number, total protein, a verified reference protein, or tissue composition.
• Concentration and time dependence: Report DC₅₀, D_max, onset, duration, and recovery with the cell model and sampling time. Distinguish a concentration producing 50% absolute target depletion from a fitted concentration producing half of the compound's maximal effect. These are not interchangeable when the maximal effect is incomplete.
• Pathway dependence: Pair direct target loss with genetic perturbation, appropriate pathway inhibitors, or matched inactive constructs. Include controls for the perturbation itself because blocking a degradation pathway can also change baseline protein levels and cell health.
• Selectivity and biological consequences: Examine related proteins, cell viability, target transcripts, and downstream function separately. A transcriptional decrease, dying cell population, or altered antibody recognition can otherwise be mistaken for accelerated protein degradation.

For comparison across candidates, use the same biological model, exposure period, sampling procedure, and calculation convention. A low DC₅₀ does not necessarily indicate deep or durable depletion, and a high D_max does not explain selectivity. If absolute depletion never reaches 50%, report that an absolute-depletion DC₅₀ was not reached rather than extrapolating a convincing-looking value. Recovery experiments should also distinguish protein resynthesis from continued intracellular degrader exposure.

PROTAC Activity and Degradation Efficiency Evaluation Methods

PROTAC evaluation links intracellular target engagement to E3-dependent ubiquitination and proteasomal removal. The most useful starting point is a concentration-by-time experiment, followed by tests that identify why strong binding does or does not translate into protein loss.

In Vitro Evaluation: DC₅₀, D_max, Degradation Kinetics, Target Ubiquitination

Measure target abundance across a concentration series using quantitative Western blotting, capillary immunoassays, or a validated endogenous-tag reporter. Include early measurements to capture onset and later measurements to establish the plateau. Keep immunoblot signals within their quantitative range and analyze viability in parallel. If degradation weakens at high concentrations, investigate a possible hook effect rather than forcing the entire curve into a monotonic fit. Report the observed concentration window and uncertainty alongside DC₅₀ and D_max.

To connect target loss with mechanism, enrich the target and detect associated ubiquitin under conditions that distinguish target ubiquitination from ubiquitinated binding partners. A brief proteasome-blocking condition in separate samples can help capture rapidly consumed ubiquitinated species. Compare the active degrader with the parent target ligand, an inactive degrader analog, and E3-deficient cells where available. A PROTAC ternary complex assay can identify a recruitment bottleneck, but ternary proximity should not replace measurement of actual degradation.

In Vivo Evaluation: Tissue Target Degradation, Degradation Duration, Target Recovery, Dose-Response

For animal studies, pair tissue target measurements with degrader concentrations in plasma and the tissue of interest. Quantitative immunoblotting or targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides abundance data; immunohistochemistry or cell-resolved imaging identifies where depletion occurs. Sample around the expected onset, deepest depletion, and recovery phase. Include a dose range that can reveal incomplete delivery or an exposure plateau, rather than evaluating only one high dose.

Define degradation duration using a prespecified depletion threshold relevant to the project. Recovery requires follow-up after dosing stops, with exposure measured where feasible: persistent depletion while compound remains in tissue is not equivalent to persistence after compound clearance. Compare protein abundance within the relevant cell population so that tissue damage or changes in cell composition do not create a false degradation signal.

Table 1. PROTACs Activity and Degradation Evaluation Summary

Molecular Glue Degrader Activity and Degradation Efficiency Evaluation Methods

A molecular glue can cause an E3 ligase system to recognize a protein that it would not otherwise efficiently degrade. That newly recruited protein is often called a neosubstrate. Evaluation must establish which proteins disappear and which losses are direct rather than secondary responses.

In Vitro Evaluation: Neosubstrate Degradation, DC₅₀, D_max, E3 Dependency

For a known neosubstrate, measure concentration-dependent depletion using endogenous-protein immunoblotting or an appropriately validated reporter. For an uncertain target profile, start with quantitative proteomics at an early, minimally cytotoxic time point, then confirm candidate substrates individually. Add ubiquitination measurements and target transcript analysis to distinguish accelerated protein turnover from reduced production. Early loss of a protein does not automatically prove direct recruitment, especially when its binding partners also become unstable.

Test the proposed E3 component by depletion or knockout and, where practical, restoration with a functional construct. Drug-dependent interaction assays or reconstituted ubiquitination can provide additional mechanistic evidence. Use targeted assays to establish DC₅₀ and D_max for each confirmed substrate rather than assigning one degradation value to the entire molecule. In molecular glue technology development, this combination helps separate a potent selective degrader from a compound that broadly changes the proteome.

In Vivo Evaluation: Tissue Target Depletion, Degradation Duration, Dose-Response

Before selecting an animal model, test whether the relevant target and E3 system support the intended response in that species or in the introduced target-expressing cells. Then measure each priority neosubstrate in the tissue of interest across dose and time. Use matched control tissues, spatial protein analysis, and exposure measurements to distinguish distribution limits from a nonresponsive molecular interaction.

A useful study report presents the intended target alongside a small panel of additional responsive proteins identified during cellular profiling. This allows the team to see whether increasing dose improves desired depletion or merely expands the protein-loss profile. Define duration from the target measurement itself, not from downstream growth inhibition or another persistent phenotype.

Table 2. Molecular Glues Activity and Degradation Evaluation Summary

SNIPER Activity and Degradation Efficiency Evaluation Methods

SNIPERs recruit inhibitor of apoptosis proteins (IAPs) for target degradation. Their evaluation should monitor both the target and relevant IAP proteins because the recruiting machinery can itself decrease during treatment.

In Vitro Evaluation: Target Degradation, DC₅₀, D_max, IAP Dependency

Measure the target together with cIAP1 and XIAP, as appropriate for the chosen ligand and model. Determine DC₅₀ and D_max from target abundance, not from IAP depletion. Use an early concentration-time matrix and parallel viability or apoptosis measurements to identify a window in which protein loss can be interpreted independently of extensive cell death.

Include the unconjugated IAP ligand, the target-binding ligand, and a matched control unable to engage one binding partner. These comparisons are particularly informative because IAP loss may occur without productive target recruitment. Genetic perturbation of the candidate IAP and proteasome controls can then test the target-degradation route. For SNIPER technology development, preserve target and IAP time courses as separate outputs rather than combining them into a single activity score.

In Vivo Evaluation: Tissue Target Depletion, Degradation Duration, Dose-Response

In a suitable animal model, quantify the target and relevant IAPs in the same tissue samples across dose and time. Pair these measurements with compound exposure and tissue morphology. The key question is whether the target declines within surviving target-expressing cells, rather than simply becoming less abundant because that cell population has contracted.

Compare the timing of IAP loss, target depletion, and downstream responses. If higher exposure removes the recruiting IAP without improving target depletion, this should guide candidate optimization rather than be reported as stronger target degradation. Animal evidence exists for selected SNIPERs, but an effective sampling schedule and responsive IAP-target combination still need to be established for each new program.

Table 3. SNIPERs Activity and Degradation Evaluation Summary

BioPROTAC Activity and Degradation Efficiency Evaluation Methods

BioPROTACs use engineered biological constructs to connect target recognition with ubiquitin-ligase activity. For expressed constructs, delivery and protein expression become experimental variables that must be separated from the efficiency of the degrader itself.

In Vitro Evaluation: Target Depletion, Expression-Normalized Degradation, Degradation Kinetics

Measure the BioPROTAC and its target in the same experiment using dual-channel flow cytometry, quantitative imaging, or paired immunoblots. Compare target depletion within matched expression ranges rather than comparing only the average response of differently transfected cultures. Report the fraction of cells expressing the construct as well as the degree of target loss within those cells. A population average can conceal strong degradation in a small subset or weak degradation in most cells.

For expression-normalized evaluation, use expression-matched groups or a calibrated relationship between construct abundance and target loss; simply dividing percentage depletion by reporter fluorescence does not create an intrinsic potency value. Include binding-deficient and ligase-recruitment-deficient constructs with comparable expression and localization. Follow target loss after induction and recovery after expression is switched off. These controls are central to BioPROTAC technology development.

In Vivo Evaluation: Tissue Expression, Target Protein Depletion, Degradation Duration

For an expressed BioPROTAC, determine where the delivered material produces the actual degrader protein. RNA detection or vector abundance can support delivery analysis, but neither substitutes for protein expression. Combine construct-protein measurement with cell-type markers and target abundance in tissue sections or isolated cells. Include an inactive construct delivered with the same formulation to separate carrier effects from degrader activity.

Measure expression duration and target-depletion duration separately. A target may remain low because expression continues, while another may recover despite detectable construct. Present the proportion of tissue cells reached, depletion within reached cells, and whole-tissue depletion as distinct results. These outputs help determine whether the next development step should improve delivery, intracellular localization, or the target-binding and ligase modules.

Table 4. BioPROTACs Activity and Degradation Evaluation Summary

LYTAC Activity and Degradation Efficiency Evaluation Methods

LYTACs direct extracellular or membrane-associated targets toward lysosomes through an internalizing receptor. Evaluation should follow the target from binding and uptake to loss of intact protein, rather than treating intracellular accumulation as the final endpoint.

In Vitro Evaluation: Target Internalization, Lysosomal Colocalization, Target Depletion, Degradation Kinetics

First verify expression of the recruited receptor in the chosen cells. Measure uptake with a pulse-chase design: distinguish material bound at the surface from internalized material using a validated surface-stripping or extracellular-quenching procedure. Follow trafficking by confocal microscopy with endosomal and lysosomal markers. A pH-sensitive label can indicate delivery to an acidic compartment, but it does not show that the target has been proteolytically destroyed.

For membrane targets, combine noncompeting-antibody flow cytometry with a total-protein assay. For soluble targets, analyze both culture medium and cell-associated material over time, using conditions that detect intact target rather than only retained fluorescent label. Receptor competition or genetic perturbation and lysosomal-function controls help establish the pathway. In LYTAC degradation technology development, the key decision is whether uptake leads to sustained total-target loss or merely redistribution.

In Vivo Evaluation: Tissue Target Depletion, Extracellular Target Clearance, Degradation Duration

Select animal measurements according to the target compartment. A membrane-target program needs tissue or cell-resolved protein analysis, whereas a circulating-target program needs repeated blood sampling with a target assay that remains reliable in the presence of the LYTAC. Where relevant, pair both with analysis of the receptor-bearing clearance tissue. Include exposure and receptor-distribution information when interpreting differences among tissues.

Measure free and total target separately when binding can mask epitopes or alter assay recovery. A declining plasma signal may indicate binding interference, redistribution, or actual clearance; evidence from target uptake and degradation is needed to distinguish them. Follow the target after treatment ends to determine the duration of depletion and replenishment. For a new construct, treat this as a model-specific evaluation plan rather than assuming the behavior of a published LYTAC.

Table 5. LYTACs Activity and Degradation Evaluation Summary

AbTAC Activity and Degradation Efficiency Evaluation Methods

AbTACs are antibody-based constructs that recruit a membrane-associated E3 ligase to a surface target. Published work supports receptor-dependent lysosomal target loss; the experimental challenge is to distinguish that process from antibody occupancy and internalization alone.

In Vitro Evaluation: Cell-Surface Target Depletion, Internalization Rate, Lysosomal Trafficking

Use a detection antibody that does not compete with the target-binding arm of the AbTAC. Otherwise, occupied epitopes can appear to be missing proteins. Measure surface abundance in viable cells and confirm total-target loss by immunoblotting or another orthogonal assay. A cell-surface biotinylation pulse-chase can separately track internalization and recycling of the original surface pool, making it useful when receptor redistribution complicates interpretation.

Compare the intact AbTAC with the individual binding arms, a nonbinding control, and cells with reduced expression of the recruited membrane E3. Examine lysosomal trafficking and test whether appropriately controlled lysosomal inhibition prevents total-target loss. When planning AbTAC degradation technology development, do not assume that recruitment of a membrane E3 makes proteasomal degradation the relevant endpoint.

In Vivo Evaluation: Tissue Target Depletion, Cell-Surface Protein Reduction, Degradation Duration

For a proposed animal study, verify that both antibody arms recognize their intended proteins in the selected model. Then combine tissue target quantification with flow cytometry of freshly isolated viable cells, using a dissociation procedure checked for effects on the measured surface protein. Spatial imaging can help distinguish depletion within target-positive cells from changes in the abundance of those cells.

Collect sufficient time points to establish target reduction and recovery, while measuring intact construct exposure where feasible. Include a binding control that lacks productive E3 recruitment to separate degradation from ordinary antibody-driven trafficking. If surface protein decreases but total tissue target remains unchanged, the next question is whether the protein has been internalized, recycled, or redistributed rather than degraded.

Table 6. AbTACs Activity and Degradation Evaluation Summary

MoDE-A Activity and Degradation Efficiency Evaluation Methods

MoDE-As connect an extracellular protein with the asialoglycoprotein receptor (ASGPR), enabling receptor-mediated uptake and lysosomal processing. Their central endpoint is removal of the extracellular target, not simply increased binding to receptor-bearing cells.

In Vitro Evaluation: Target Binding, ASGPR-Mediated Uptake, Lysosomal Degradation

Begin with target binding and productive receptor-dependent uptake. Binding affinity can be measured by surface plasmon resonance or biolayer interferometry when suitable reagents are available, but uptake should be tested in receptor-positive cells. Include receptor-negative or receptor-reduced cells, competition controls, and an inactive receptor-binding analog where practical. These comparisons help determine whether low activity reflects failed target recognition or failed receptor engagement.

Track the extracellular target through medium depletion, cellular uptake, and disappearance of intact intracellular protein. Use pulse-chase experiments and lysosomal controls to separate uptake from breakdown. Check that the detection assay measures the target in the presence of excess degrader and any formed complexes. For MoDE-A technology development, concordant compartment measurements are more informative than a single fluorescence endpoint.

In Vivo Evaluation: Circulating Target Clearance, Clearance Rate, Target Recovery

Use serial blood samples to measure target concentration before treatment, during depletion, and through recovery. Where feasible, complement the circulating profile with evidence of uptake and processing in the liver. Validate assay recovery for both free and degrader-bound target; a binding-induced loss of immunoassay signal must not be reported as protein elimination.

Report baseline-normalized target reduction and an apparent depletion rate or half-time only when the sampling and kinetic model support them. A continuously synthesized endogenous protein does not necessarily follow simple exponential decay. Its depletion rate is also not the pharmacokinetic clearance of the MoDE-A molecule. Recovery data should account for ongoing target production and declining degrader exposure, helping the team judge whether repeated administration would maintain depletion.

Table 7. MoDE-As Activity and Degradation Evaluation Summary

KineTAC Activity and Degradation Efficiency Evaluation Methods

KineTACs use cytokine or chemokine receptor engagement to internalize an attached target-binding construct and its cargo. Evaluation must separate the effects of the recruiting ligand from actual loss of the intended target.

In Vitro Evaluation: Receptor-Mediated Internalization, Target Depletion, Lysosomal Trafficking

Confirm the receptor used by the particular construct rather than assuming receptor usage from the cytokine name. Compare the complete KineTAC with the recruiting ligand alone, the target binder alone, and a nonbinding construct. Use receptor perturbation or competition to test dependence. Quantify uptake and trafficking, then measure total target abundance to determine whether recruitment produces degradation rather than temporary sequestration.

For surface targets, combine viable-cell surface measurements with endogenous total-protein detection. For soluble targets, follow medium and cell-associated target together. Measure relevant cytokine-response markers separately so that ligand-driven signaling is not mistaken for a consequence of degradation. In KineTAC technology development, these paired controls help identify whether optimization should focus on receptor selection, cargo binding, or intracellular routing.

In Vivo Evaluation: Tissue Target Depletion, Soluble Target Clearance, Degradation Duration

For an animal evaluation plan, first verify compatibility of the recruiting receptor, ligand, and target binder in the chosen model. Map the target response against construct exposure and receptor-bearing cell populations. Measure tissue protein for membrane targets and serial circulating protein for soluble targets; use both when the biological question requires them.

Assess target loss within the relevant cells alongside changes in cell composition, because cytokine-driven effects can alter the abundance or distribution of those cells. Include the recruiting-ligand control and an inactive target-binding control where practical. Demonstrating persistence of the construct in blood is an exposure result, not evidence of sustained target degradation. Degradation duration must come from repeated target measurements.

Table 8. KineTACs Activity and Degradation Evaluation Summary

AUTAC Activity and Degradation Efficiency Evaluation Methods

AUTACs are designed to promote selective autophagic disposal of tagged cargo. Depending on the construct, that cargo may be a protein or an organelle-associated target. Evaluation should therefore define what is being removed before choosing an autophagy marker.

In Vitro Evaluation: Target Clearance, LC3 Recruitment, Autophagic Flux, Degradation Kinetics

For a protein target, quantify endogenous abundance across concentration and time. For organelle-directed constructs, combine cargo-marker measurements with organelle-resolved imaging, rather than relying on a single membrane-potential dye. Examine cargo-associated ubiquitination where relevant to the proposed AUTAC mechanism, followed by recruitment to LC3-positive structures and subsequent target disappearance. A decrease in one organelle marker should not automatically be interpreted as clearance of the entire organelle.

Test autophagic flux using a suitable tandem fluorescent LC3 reporter or paired turnover measurements with and without a controlled lysosomal block. More LC3 puncta can reflect either increased delivery or impaired disposal, so static puncta counts cannot settle that distinction. Add a relevant autophagy-gene perturbation and verify target loss with an independent protein assay. In AUTAC degradation technology development, these experiments distinguish selective cargo clearance from a general stress response.

In Vivo Evaluation: Tissue Target Clearance, Aggregate Reduction, Autophagy Activation

For an animal study, select the tissue and cargo fraction before setting the dose schedule. Measure target protein in the relevant cell population and, only for an aggregate-bearing target, quantify aggregate number, size, and insoluble-protein abundance. For an organelle-directed AUTAC, replace aggregate endpoints with organelle-content and functional measurements appropriate to that project.

Assess pathway engagement alongside target clearance rather than using a rise in LC3 or a fall in p62 as proof of success. Reporter models or carefully designed tissue-derived flux studies may help, but static tissue staining remains supporting evidence. Control sampling time, tissue processing, and viable cell abundance. An informative result shows selective cargo loss without interpreting generalized tissue injury or organelle depletion as improved degradation efficiency.

Table 9. AUTACs Activity and Degradation Evaluation Summary

ATTEC Activity and Degradation Efficiency Evaluation Methods

ATTECs aim to connect a target with LC3-family autophagy machinery. Published studies describe target lowering, but subsequent work has challenged direct LC3 binding for some reported ligands. An evaluation plan should therefore verify the proposed binding mechanism for the actual compound being tested.

In Vitro Evaluation: Target-LC3 Interaction, Aggregate Clearance, Autophagic Flux

Test target binding and LC3 binding independently, then examine compound-dependent proximity. Use complementary binding approaches, such as surface plasmon resonance and nuclear magnetic resonance, where the reagents and expected affinity permit. Include controls for nonspecific adsorption, compound aggregation, fluorescence interference, and loss of binding after conjugation. A previously assigned LC3-binding label is not sufficient evidence for a new construct.

Measure total target and, when relevant, its soluble and insoluble fractions. Combine aggregate imaging with an independent protein assay to distinguish destruction from aggregate dissolution or altered staining. Test autophagy dependence and demonstrate cargo delivery into a functioning degradative pathway. Global LC3 activity need not increase for selective target clearance to occur. For ATTEC degradation technology development, binding validation and direct cargo measurements should advance together.

In Vivo Evaluation: Tissue Aggregate Reduction, Target Clearance, Degradation Duration

For an appropriate animal model, quantify target abundance in the tissue region and cell type relevant to the intended response. If the target forms aggregates, combine fixed-tissue imaging with biochemical fractionation of separately collected tissue. Keep soluble-target loss and insoluble-target loss distinct, and measure a relevant unaffected protein or protein variant when selectivity is part of the design objective.

Follow clearance during exposure and after dosing stops. A reduction in aggregate area without a decrease in target protein can reflect redistribution among physical states, so it should not be described as equivalent to total protein degradation. Interpret tissue findings together with the compound-specific LC3-binding and autophagy-dependence evidence established earlier, rather than assuming that an animal response resolves an uncertain molecular mechanism.

Table 10. ATTECs Activity and Degradation Evaluation Summary

AUTOTAC Activity and Degradation Efficiency Evaluation Methods

AUTOTACs recruit the autophagy receptor p62/SQSTM1 to promote target sequestration and lysosomal disposal. Evaluation should separate p62 engagement and assembly from the subsequent removal of the target protein.

In Vitro Evaluation: p62 Recruitment, Aggregate Clearance, Autophagic Flux

Use binding or pull-down assays to examine p62 engagement and imaging or suitable assembly assays to assess target-associated p62 bodies. When oligomerization is an endpoint, distinguish p62 assembly from a simple increase in its expression. Include the target-binding component, the p62-binding component, and an inactive conjugate where available, so that the effect of the complete AUTOTAC can be compared with each component separately.

Measure soluble and insoluble target fractions over time and pair these data with aggregate imaging. Test whether depletion of p62 or an appropriate autophagy component prevents target loss. Flux measurements should establish that cargo proceeds toward disposal rather than accumulating in p62-positive structures. Because p62 is both a receptor and a protein whose abundance can change during autophagy, its steady-state level is not a stand-alone degradation-efficiency measurement.

In Vivo Evaluation: Tissue Aggregate Reduction, Target Clearance, Autophagy Activation

Where an animal model is appropriate, quantify the target in tissue fractions and use spatial imaging to determine whether aggregate burden decreases in the intended cells. Report aggregate number, occupied area, and biochemical target abundance separately. These measurements answer different questions and should not be collapsed into a single percentage without a clear definition.

Assess p62-associated recruitment and pathway activity as supporting endpoints, while keeping target clearance as the primary outcome. Use tissue exposure, cell viability, and sampling consistency to evaluate weak or variable responses. Changes described as autophagy activation should not be presented as proof that a particular target has been degraded. The strongest candidate comparison combines direct target loss, relevant pathway dependence, and preservation of the surrounding cell population.

Table 11. AUTOTACs Activity and Degradation Evaluation Summary

CMA-Based Degrader Activity and Degradation Efficiency Evaluation Methods

Chaperone-mediated autophagy (CMA) uses HSC70 recognition and LAMP-2A-dependent lysosomal import. Unlike macroautophagy, it transports individual protein substrates across the lysosomal membrane rather than enclosing bulky cargo in an autophagosome.

In Vitro Evaluation: HSC70 Recruitment, LAMP-2A Dependency, Target Depletion

Begin with cellular uptake, cytosolic availability, and target engagement for the proposed degrader. Examine target association with HSC70 by co-immunoprecipitation or a suitable interaction assay, then test target depletion in control and LAMP-2A-perturbed cells. Use isoform-specific measurements: total LAMP2 abundance does not establish the involvement of LAMP-2A. Include an inactive targeting motif or binding-deficient control where the construct design allows.

To examine the transport step, use an isolated-lysosome uptake assay with membrane-integrity and protease-protection controls. Protein attached to the outside of a lysosome must be distinguished from protein imported into its lumen. Pair transport evidence with cellular target loss and recovery, and use additional pathway controls when macroautophagy could contribute. For CMA-based degradation technology development, these tests are more specific than lysosomal colocalization alone.

In Vivo Evaluation: Tissue Target Depletion, Lysosomal Pathway Engagement, Degradation Duration

Design tissue sampling around both target depletion and the stability or expression of the degrader format. Quantify target protein by immunoblotting, a validated immunoassay, or targeted proteomics, supported by cell-resolved imaging. For peptide-based constructs, measure intact-peptide exposure where feasible; detection of a retained label does not necessarily establish that the functional construct remains intact.

Reserve suitable fresh material for tissue-derived lysosomal uptake studies when direct transport evidence is required. These supporting experiments must be identified as ex vivo measurements, not direct observation of import in the animal. Follow target recovery and assess whether the cellular evidence supports HSC70/LAMP-2A dependence. Do not infer CMA clearance of intact aggregates from reduced aggregate staining: import of individual protein substrates and disposal of large assemblies are different processes.

Table 12. CMA Degraders Activity and Degradation Evaluation Summary

Conclusion

Protein degrader evaluation is not a single assay but a chain of evidence, and the chain has to be built differently for each class. A PROTAC must be shown to assemble a ternary complex, transfer ubiquitin, and release its target to the proteasome. A molecular glue must be shown to create a new interface and to do so without sweeping up unintended substrates. An antibody-based or receptor-recruiting degrader must be shown to internalize, to sort toward the lysosome rather than back to the surface, and to reduce total protein rather than merely redistribute it. An autophagy-directed molecule must be shown to engage its receptor and to complete the route rather than stall inside it.

Across all of them, four habits separate datasets that support decisions from datasets that merely fill reports. The first is reporting potency with its context: a DC₅₀ without treatment time, cell model, and detection method cannot be compared with anything. The second is measuring depth alongside potency, because a compound that removes a third of its target is a different proposition from one that removes nearly all of it. The third is measuring time, since onset, peak, and recovery together describe the pharmacology in a way that no endpoint can. The fourth is proving the mechanism, because target loss alone is compatible with too many explanations to be persuasive.

Get those four right, and the class-specific details become straightforward extensions rather than sources of ambiguity. Get them wrong, and no amount of additional compounds will resolve the uncertainty.

BOC Sciences Support for Protein Degrader Activity Evaluation

BOC Sciences provides evaluation support across every degrader class described above, built around the principle that the assay must match the mechanism. Programs are designed from the target and the intended degradation route outward, so that potency, depth, kinetics, pathway dependence, selectivity, and tissue-level effect are measured in a single coordinated dataset rather than assembled from unrelated studies.

Quantitative Target Protein Degradation Assays

• Full dose–response and time-course design reporting DC₅₀, D_max, degradation rate, time to maximum effect, and recovery half-life
• Detection by quantitative immunoblot, capillary immunoassay, plate-based reporter, flow cytometry, or targeted mass spectrometry, selected according to target abundance and antibody performance
• Integrated PROTAC in vitro evaluation combining cellular degradation, mechanism validation, permeability, and stability readouts in one study

Degradation Mechanism and Pathway Validation

• Ternary complex formation, ligase engagement, and target ubiquitination assessed in matched conditions, supported by protein ubiquitination services
• Route-dependence controls for proteasomal, endocytic–lysosomal, and autophagic degradation, including ligase knockout, receptor knockdown, and inhibitor rescue arms
• Transcription, translation, and cytotoxicity counter-screens to exclude non-degradative explanations for target loss

Cellular Uptake and Intracellular Trafficking Analysis

• Surface versus total protein quantification, internalization kinetics, and endosomal-to-lysosomal sorting for extracellular and membrane targets
• Compartment co-localization and organelle accessibility assessment to explain binding without degradation
• Permeability and intracellular exposure measurement for bifunctional degraders whose cellular activity is limited by entry

Degrader Candidate Screening and Comparative Evaluation

• PROTAC high-throughput screening for ranking analog series on degradation depth, potency, and hook-window width
• Head-to-head comparison tables across candidates, with decision criteria defined before the study begins
• Proteome-level selectivity and focused off-target panels applied at the point where a series is being narrowed

Explore featured products that can expand your research options and accelerate your next discovery.

Access end-to-end service solutions that help bring efficiency, flexibility, and expertise to your research pipeline.

News

• Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology
• Degrader Building Blocks for Targeted Protein Degradation
• Recent Progress of PROTACs Targeting Non-enzymatic Functional Proteins
• Discovery of Molecular Glue Degraders

Technical Information

• Proteolysis-Targeting Chimeras (PROTAC)
• Overview of 12 Targeted Protein Degradation Technologies
• Introduction to Lysosome-Based Degradation Technologies
• Research Progress of Extracellular Targeted Protein Degradation Technology